Preprint: Advances in Multi-parameter Optimisation Methods for de Novo Drug Design

by Thanos Panagiotidis | Apr 7, 2014 | Multi-Parameter Optimisation, Publications and presentations

Preprint: Advances in Multi-parameter Optimisation Methods for de Novo Drug Design This review article has just been accepted by Expert Opinion in Drug Discovery and discusses recent developments in the methods and opinions in multi-parameter optimisation, focusing on...

Addressing Toxicity Risk when Designing and Selecting Compounds in Early Drug Discovery Presentation

by Thanos Panagiotidis | Apr 2, 2014 | Drug Discovery Applications, Publications and presentations

Addressing Toxicity Risk when Designing and Selecting Compounds in Early Drug Discovery Presentation Ed Champness gave this presentation at the ACS Spring 2014 National Meeting & Exposition held in Dallas, USA on 19th March 2014. Abstract It has been estimated...

Predictive Application of Bioisostere Transformations to Identify Novel High Quality Compound Ideas

by Thanos Panagiotidis | Apr 2, 2014 | Drug Discovery Applications, Publications and presentations

Predictive Application of Bioisostere Transformations to Identify Novel High Quality Compound Ideas Ed Champness gave this presentation at the ACS Spring 2014 National Meeting & Exposition held in Dallas, USA on 17th March 2014. Abstract We will describe how the...

Advances in Multi-Parameter Optimisation: Targeting the ‘best’ profile for your project’s objectives

by Thanos Panagiotidis | Apr 2, 2014 | Multi-Parameter Optimisation, Publications and presentations

Advances in Multi-Parameter Optimisation: Targeting the ‘best’ profile for your project’s objectives Ed Champness gave this presentation at the ACS Spring 2014 National Meeting & Exposition held in Dallas, USA on 16th March 2014. Abstract Multi-parameter...

Recent Posts

  • Optibrium appoints Steve Yemm as Chief Commercial Officer
  • Introduction to StarDrop™
  • Real world case studies: Predicting pharmacokinetics from limited ADME data with deep learning
  • Inspyra™– Introduction
  • Cerella™– Introduction

Archives

Categories

  • Asteris
  • Cerella
  • Downloads
  • Drug Discovery Applications
  • Events
  • Example Code
  • General
  • In Silico Modelling
  • Latest Videos
  • Models
  • Multi-Parameter Optimisation
  • News
  • Ocura
  • Pipeline Pilot Protocols
  • Presentations and Webinars
  • Publications and presentations
  • Scoring Profiles
  • Scripts/Addons
  • StarDrop Hints and Tips
  • StarDrop Modules and Features
  • StarDrop Tutorials
  • Tutorials
  • Upcoming webinar
  • Videos
  • Webinars

Meta

  • Register
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

The Optibrium team works at the forefront of decision-analysis and predictive modelling research, developing innovative products that enhance the efficiency and productivity of drug discovery.

enquiries & support

General: [email protected]
StarDrop: [email protected]
Cerella: [email protected]
Press: [email protected]
Vacancies: [email protected]

  • Follow
  • Follow
further information

View our Privacy Policy

Copyright © 2023 Optibrium, Ltd. All Rights Reserved.
Optibrium™, StarDrop™, Augmented Chemistry®, Cerella™, Asteris™, Ocura™, Glowing Molecule™, WhichP450™, Auto-Modeller™, Nova™, MPO Explorer™ and Card View® are trademarks of Optibrium Ltd. Augmented Chemistry® is registered only in the UK and EU. Card View® is registered only in the United States. Matsy™ is a trademark of NextMove Software Ltd., BIOSTER™ is a trademark of iKem Szolgáltató és Kereskedelmi BT, Derek Nexus™ is a trademark of Lhasa Ltd., Surflex eSim3D is a trademark of BioPharmics LLC, and SeeSAR™ is a trademark of BioSolveIT GmbH. US Patent Numbers 9,224,098 and 9,367,812

Website designed and developed by Identity Creative.

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}